Compare Novartis with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs NATCO PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS NATCO PHARMA NOVARTIS/
NATCO PHARMA
 
P/E (TTM) x 1,865.2 24.0 7,755.9% View Chart
P/BV x 24.8 3.6 691.5% View Chart
Dividend Yield % 1.8 0.9 189.3%  

Financials

 NOVARTIS   NATCO PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-19
NATCO PHARMA
Mar-19
NOVARTIS/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs980849 115.4%   
Low Rs600557 107.8%   
Sales per share (Unadj.) Rs198.7573.8 34.6%  
Earnings per share (Unadj.) Rs21.0176.0 11.9%  
Cash flow per share (Unadj.) Rs22.3198.2 11.2%  
Dividends per share (Unadj.) Rs10.006.25 160.0%  
Dividend yield (eoy) %1.30.9 142.4%  
Book value per share (Unadj.) Rs307.5842.7 36.5%  
Shares outstanding (eoy) m24.6936.50 67.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.01.2 324.5%   
Avg P/E ratio x37.74.0 943.4%  
P/CF ratio (eoy) x35.53.5 1,000.8%  
Price / Book Value ratio x2.60.8 308.0%  
Dividend payout %47.73.6 1,343.0%   
Avg Mkt Cap Rs m19,50825,660 76.0%   
No. of employees `0000.65.0 11.7%   
Total wages/salary Rs m1,1713,559 32.9%   
Avg. sales/employee Rs Th8,445.44,225.3 199.9%   
Avg. wages/employee Rs Th2,015.7718.0 280.7%   
Avg. net profit/employee Rs Th891.01,295.9 68.8%   
INCOME DATA
Net Sales Rs m4,90720,945 23.4%  
Other income Rs m7831,302 60.1%   
Total revenues Rs m5,68922,247 25.6%   
Gross profit Rs m1237,948 1.5%  
Depreciation Rs m32810 3.9%   
Interest Rs m16193 8.2%   
Profit before tax Rs m8588,247 10.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3401,823 18.7%   
Profit after tax Rs m5186,424 8.1%  
Gross profit margin %2.537.9 6.6%  
Effective tax rate %39.622.1 179.3%   
Net profit margin %10.630.7 34.4%  
BALANCE SHEET DATA
Current assets Rs m8,05523,472 34.3%   
Current liabilities Rs m1,8507,287 25.4%   
Net working cap to sales %126.477.3 163.6%  
Current ratio x4.43.2 135.2%  
Inventory Days Days4592 48.8%  
Debtors Days Days3488 38.4%  
Net fixed assets Rs m15018,648 0.8%   
Share capital Rs m123365 33.8%   
"Free" reserves Rs m7,46934,525 21.6%   
Net worth Rs m7,59230,760 24.7%   
Long term debt Rs m00-   
Total assets Rs m9,82443,031 22.8%  
Interest coverage x54.943.7 125.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.5 102.6%   
Return on assets %5.415.4 35.3%  
Return on equity %6.820.9 32.7%  
Return on capital %11.527.4 41.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5811,536 0.5%   
Fx outflow Rs m1,3262,939 45.1%   
Net fx Rs m-1,2698,597 -14.8%   
CASH FLOW
From Operations Rs m-1,9436,688 -29.0%  
From Investments Rs m2,742-6,122 -44.8%  
From Financial Activity Rs m-298-509 58.6%  
Net Cashflow Rs m50166 759.5%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 1.5 5,102.0%  
Indian inst/Mut Fund % 2.0 7.8 25.5%  
FIIs % 1.6 16.6 9.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 26.0 82.7%  
Shareholders   41,647 25,395 164.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

The Triple Digit Return Opportunity in this Market

Jun 24, 2020

Rahul Shah on stocks with potentially triple digit returns.

This Ratio Says Smallcaps Are Your Best Bet to Ride the Post Covid Market Rebound(Profit Hunter)

Jun 23, 2020

Here's why I believe that post Covid rebound in smallcaps will be much sharper than largecaps.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 3, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS